Stay updated on Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial

Sign up to get notified when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov study record for reirradiation with pembrolizumab is displayed, including study design, eligibility criteria, outcomes, locations, and posted results.
    Difference
    55%
    Check dated 2026-11-08T14:44:30.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-01T15:50:19.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A site-wide NIH announcement banner describes a transition from “Artificial Intelligence” to “Super Intelligence” terminology under Executive Order 14434. The study record still displays a 403 error.
    Difference
    1%
    Check dated 2026-10-25T17:41:38.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:27:41.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-11T22:24:13.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page currently displays a 403 Forbidden error, blocking access to the study record and its content. The 403 page replaces the usual ClinicalTrials.gov study details with an access-denied message.
    Difference
    19%
    Check dated 2026-09-20T22:36:57.000Z thumbnail image

Stay in the know with updates to Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.